16S rRNA gene sequencing of the gut microbiota in polycystic ovary syndrome (PCOS) rats following gypenosides intervention
This study investigates the effects of gypenosides on the gut microbiota structure in a rat model of polycystic ovary syndrome (PCOS). PCOS is a common endocrine and metabolic disorder, and emerging evidence suggests a potential link between its pathogenesis and gut microbiota dysbiosis. Gypenosides have been reported to possess various pharmacological properties, including anti-inflammatory, antioxidant, and metabolic regulatory effects. However, whether they ameliorate PCOS via modulating the gut microbiota remains unclear.A PCOS rat model was established and divided into three groups: normal control (Control), PCOS model (PCOS-Model), and gypenoside-treated PCOS (PCOS-Gyp). Fecal samples were collected from 4 rats per group (12 total). The gut microbial communities were profiled using high-throughput 16S rRNA gene amplicon sequencing (V3-V4 region) to systematically compare their composition, diversity, and structure across groups.The project aims to: 1) determine whether PCOS induction significantly alters the gut microbiota compared to controls; 2) assess if gypenoside intervention reverses PCOS-associated microbial dysbiosis; and 3) identify key microbial taxa or functional modules associated with the treatment response. This research will provide data to elucidate the potential microbiological mechanisms underlying gypenoside's efficacy in PCOS and inform novel microecological therapeutic strategies.The submitted dataset comprises raw sequencing files (FASTQ format) and sample metadata from all 12 samples, suitable for downstream bioinformatic analyses such as microbial community comparison, diversity assessment, and differential abundance analysis.